<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Myotonic dystrophy: Etiology, clinical features, and diagnosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Myotonic dystrophy: Etiology, clinical features, and diagnosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Myotonic dystrophy: Etiology, clinical features, and diagnosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Basil T Darras, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeremy M Shefner, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Douglas R Nordli, Jr, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John F Dashe, MD, PhD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 22, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Myotonic dystrophy (DM) is a clinically and genetically heterogeneous disorder. There are two major forms:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         DM1, for a century known as Steinert disease
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         DM2, recognized in 1994 as a milder version of DM1
        </p>
        <p>
        </p>
        <p>
         These autosomal dominant conditions are among the most common forms of adult-onset muscular dystrophy. However, DM is more than simply a muscular dystrophy per se, since affected individuals may show cataracts, cardiac conduction abnormalities, infertility, and insulin resistance. Furthermore, there is a severe congenital form of DM1 with marked developmental disability.
        </p>
        <p>
         One consequence of the multisystemic nature of this disorder is that individuals affected by DM1 or DM2 may first present to internists, cardiologists, ophthalmologists, endocrinologists, and pediatricians (in the case of DM1), before they see a neurologist.
        </p>
        <p>
         The genetics, pathophysiology, clinical features, and diagnosis of DM will be reviewed here. The prognosis and management of DM are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5140.html" rel="external">
          "Myotonic dystrophy: Treatment and prognosis"
         </a>
         .)
        </p>
        <p>
         Other muscular dystrophies are also discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6149.html" rel="external">
          "Duchenne and Becker muscular dystrophy: Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6185.html" rel="external">
          "Emery-Dreifuss muscular dystrophy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6190.html" rel="external">
          "Limb-girdle muscular dystrophy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6180.html" rel="external">
          "Oculopharyngeal, distal, and congenital muscular dystrophies"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          GENETICS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Myotonic dystrophy type 1 (DM1) results from an expansion of a cytosine-thymine-guanine (CTG) trinucleotide repeat in the 3'-untranslated region of the dystrophia myotonica protein kinase (
         <em>
          DMPK
         </em>
         ) gene on chromosome 19q 13.3 [
         <a href="#rid1">
          1-5
         </a>
         ]. Wild-type individuals have 5 to 34 CTG repeats at this locus, whereas individuals with classic DM1 have repeats in the hundreds to thousands. In DM1, the expansion of a normal allele (&lt;35 repeats) into the abnormal range is rare.
        </p>
        <p>
         Myotonic dystrophy type 2 (DM2) is caused by an expanded cytosine-cytosine-thymine-guanine (CCTG) tetranucleotide repeat expansion located in intron 1 of the
         <em>
          ZNF9
         </em>
         gene, also known as the
         <em>
          CNBP
         </em>
         gene, on chromosome 3q 21.3 [
         <a href="#rid6">
          6
         </a>
         ]. On normal alleles, there are 11 to 26 tetranucleotide repeats; on pathogenic alleles, the number of repeats ranges from 75 to more than 11,000, with a mean of 5000 repeats [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         In both DM1 and DM2, the repeat expansion is transcribed into ribonucleic acid (RNA) but remains untranslated. The marked intergenerational instability of the size of the repeat expansion may explain the phenomenon of anticipation, at least in DM1, in which increased size of the expansion is associated with an earlier age of onset and more severe clinical phenotype [
         <a href="#rid8">
          8,9
         </a>
         ]. Intergenerational contraction of the CTG repeat has also been observed [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         In DM1, the length of the CTG repeat expansion is moderately correlated with disease severity and age of onset (see
         <a class="local">
          'Phenotypes'
         </a>
         below). Another factor that contributes to the variable clinical expression of DM1 is somatic mosaicism, which is due to instability of the CTG repeat expansion in somatic cells during life. The somatic instability is thought to be due to abnormal deoxyribonucleic acid (DNA) repair [
         <a href="#rid11">
          11
         </a>
         ]. The CTG expansion is particularly unstable in nondividing cells of the brain, skeletal muscle, and cardiac muscle, whereas the expansion is relatively stable in leukocytes [
         <a href="#rid12">
          12-14
         </a>
         ]; this probably explains why CTG repeat lengths are 5- to 10-fold longer in the brain, skeletal muscle, and heart compared with CTG repeat lengths in blood leukocytes [
         <a href="#rid9">
          9
         </a>
         ]. Thus, variations in organ-specific progression of severity for an individual with DM1 are related, at least in part, to the burden of somatic mosaicism within each organ [
         <a href="#rid14">
          14,15
         </a>
         ].
        </p>
        <p>
         In DM2, there is no definite correlation between repeat length and disease severity [
         <a href="#rid7">
          7,16
         </a>
         ]. In addition, there is no maternal or paternal predilection in DM2 for repeat size contraction or expansion. While the CCTG repeat tract displays intergenerational instability, transmission to the next generation more often results in smaller rather than larger repeat lengths, such that anticipation is rare. However, the CCTG repeat tract also displays somatic instability, whereby the CCTG repeat length increases with age. These factors complicate the analysis of repeat length as related to disease onset and severity.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          PATHOPHYSIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         DM provides an example of a novel mechanism of disease, that of RNA toxicity, which results from the expanded repeat in the transcripts from the mutant DM alleles [
         <a href="#rid17">
          17
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In myotonic dystrophy type 1 (DM1), the expanded trinucleotide repeat is located in the 3'-untranslated region of the dystrophia myotonica protein kinase (
         <em>
          DMPK
         </em>
         ) gene, and also happens to be located within the promoter region of the adjacent
         <em>
          SIX5
         </em>
         gene.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In myotonic dystrophy type 2 (DM2), the expanded tetranucleotide repeat is located within the first intron of the
         <em>
          ZNF9
         </em>
         (
         <em>
          CNBP
         </em>
         ) gene.
        </p>
        <p>
        </p>
        <p>
         In each instance, the gene is transcribed into RNA but is not translated. It is notable that DMPK, a serine-threonine kinase, shows no functional similarity to ZNF9 (CNBP), an RNA-binding protein. The fact that both genes were associated by repeat expansions in transcribed but untranslated regions suggests that the mutant RNA might have a significant role in the disease process [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
         Current understanding of the pathophysiology of this disease posits what is known as a "trans" effect, in which the repeat expansions exert a dominant toxic effect on other genes not localized to either the DM1 or DM2 loci. This effect is mediated by two RNA-binding protein families [
         <a href="#rid19">
          19,20
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Muscleblind-like (MBNL)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CUG-BP- and ETR-3-like-factors (CELF)
        </p>
        <p>
        </p>
        <p>
         According to this theory, for which there is some experimental support, the cytosine-uracil-guanine (CUG) and cytosine-cytosine-uracil-guanine (CCUG) RNA expansions fold into a hairpin structure, and these mutant RNAs accumulate in the nucleus [
         <a href="#rid21">
          21
         </a>
         ]. In DM1, the mutant CUG repeat containing RNA sequesters MBNL1 and leads to loss of its function [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
         The mutant RNAs alter RNA-binding protein activity, which in turn results in aberrant splicing and abnormal function of several genes, including the bridging integrator 1 gene (
         <em>
          BIN1
         </em>
         ) [
         <a href="#rid22">
          22
         </a>
         ], the skeletal muscle chloride channel [
         <a href="#rid23">
          23
         </a>
         ], the insulin receptor [
         <a href="#rid24">
          24
         </a>
         ], and cardiac troponin T [
         <a href="#rid25">
          25
         </a>
         ]. Muscle weakness may result from sequestration of MBNL1 by expanded CUG or CCUG repeats, leading to alternative splicing of the
         <em>
          BIN1
         </em>
         gene and skipping of muscle-specific exon 11 of
         <em>
          BIN1
         </em>
         messenger RNA, which in turn causes disorganized T tubules and impairs excitation-contraction coupling  (
         <a class="graphic graphic_figure graphicRef77706" href="/z/d/graphic/77706.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid22">
          22
         </a>
         ]. Skeletal muscle chloride channel dysfunction is responsible for the myotonia [
         <a href="#rid20">
          20,26,27
         </a>
         ] and is related to increased inclusion of exon 7A during misregulated alternative splicing of the
         <em>
          CLCN1
         </em>
         gene [
         <a href="#rid20">
          20
         </a>
         ]. Mutant RNA appears to induce expression of the cardiac transcription factor NKX2-5, which may account for the cardiac conduction disturbances associated with DM1 [
         <a href="#rid28">
          28
         </a>
         ]. Dysregulation of alpha-dystrobrevin splicing may also play a role in the muscle weakness and wasting found with DM1 [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H705139862">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         DM is the most common muscular dystrophy among adults of European ancestry. The prevalence of DM ranges from 1 in 7400 to 1 in 10,700 in Europe [
         <a href="#rid30">
          30-32
         </a>
         ]. These prevalence rates are likely to be underestimates; a 2021 study analyzing dried blood spots from the newborn screening program in the state of New York found cytosine-thymine-guanine repeat expansions ≥50, and therefore consistent with a diagnosis of DM1 in 4.76 per 10,000 births, or 1 in 2100 births [
         <a href="#rid33">
          33
         </a>
         ], which is up to five times higher than previously reported estimates. The prevalence is much higher in certain regions, including Quebec in Canada and the Basque region of Spain, suggesting a founder effect [
         <a href="#rid9">
          9,34,35
         </a>
         ]. Among Asian populations in Taiwan and Black populations in South Africa, myotonic dystrophy type 1 (DM1) is uncommon or rare [
         <a href="#rid36">
          36-39
         </a>
         ].
        </p>
        <p>
         Though less well studied, reports from Europe suggest the prevalence of myotonic dystrophy type 2 (DM2) is similar to that of DM1 [
         <a href="#rid40">
          40,41
         </a>
         ]. However, anecdotal evidence suggests that DM2 is less frequent than DM1 in the United States [
         <a href="#rid17">
          17
         </a>
         ]. In a single center in the US, DM2 was the fifth most common type of muscular dystrophy but five-fold less common than DM1 [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
         Estimates of the incidence of congenital DM vary widely, ranging from 2.1 to 28.6 per 100,000 live births in different studies, few of which were population based [
         <a href="#rid43">
          43-46
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1951197145">
         <span class="h1">
          PHENOTYPES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Myotonic dystrophy type 1 (DM1) and type 2 (DM2) are similar in that both are multisystem disorders characterized by skeletal muscle weakness and myotonia (ie, abnormally slow or delayed muscle relaxation following normal muscle contraction with a characteristic neurophysiologic signature on electromyographic [EMG] testing), cardiac conduction abnormalities, cataracts, and other abnormalities  (
         <a class="graphic graphic_table graphicRef75472" href="/z/d/graphic/75472.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef51888" href="/z/d/graphic/51888.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid15">
          15,17,47
         </a>
         ]. DM1 is further divided into congenital, childhood, classic, and mild phenotypes.
        </p>
        <p>
         In general, the severity of the DM1 phenotype correlates loosely with the cytosine-thymine-guanine (CTG) repeat size, but there is considerable variability and overlap between phenotypes  (
         <a class="graphic graphic_table graphicRef110272" href="/z/d/graphic/110272.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Individuals with a CTG repeat size between 35 and 49, designated premutation status or mutable normal, are asymptomatic.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A mutation of 50 to approximately 150 CTG repeats can manifest as a phenotype characterized by mild myotonia, weakness, or cataracts. (See
         <a class="local">
          'Mild DM1'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Repeats in the range of 50 to 1000 are seen in individuals with the classic DM1 phenotype (onset between 10 and 30 years of age) characterized by muscle wasting and weakness, myotonia, cataracts, frontal balding, and cardiac conduction defects. Average lifespan is reduced. (See
         <a class="local">
          'Classic DM1'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CTG repeat lengths &gt;500 may manifest as childhood DM1, which typically presents with cognitive and behavioral problems. Muscle weakness develops later similar to severe adult-onset classic DM1. Some cases of childhood DM1 occur in children with repeat lengths ≤500. (See
         <a class="local">
          'Childhood DM1'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         With CTG repeat lengths &gt;1000, DM1 may manifest at birth with infantile hypotonia, respiratory dysfunction, and the emergence of intellectual disability; congenital DM1 has also been observed with CTG repeat lengths between 730 and 1000. (See
         <a class="local">
          'Congenital DM1'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         DM2 is generally a less severe disease than classic DM1. (See
         <a class="local">
          'DM2'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H423148898">
         <span class="h2">
          Congenital DM1
         </span>
         <span class="headingEndMark">
          —
         </span>
         The congenital form of DM1 is characterized by profound hypotonia, facial diplegia, poor feeding, arthrogryposis (congenital joint contractures), especially of the legs, and respiratory failure [
         <a href="#rid9">
          9
         </a>
         ]. The majority of affected infants (at least 80 percent) have a characteristic "V" shape of the upper lip that results from facial diplegia [
         <a href="#rid48">
          48
         </a>
         ]. In addition to the profound hypotonia and facial weakness, physical examination also shows truncal and appendicular weakness as well as areflexia or marked hyporeflexia. Arthrogryposis usually involves at least the ankles, leading to clubfoot deformity.
        </p>
        <p>
         In some cases, DM1 may present before birth as polyhydramnios, talipes (clubfoot), and reduced fetal movement [
         <a href="#rid49">
          49
         </a>
         ]. In the most severely affected infants, polyhydramnios is common during pregnancy and is related to disturbance in swallowing [
         <a href="#rid50">
          50-55
         </a>
         ]; polyhydramnios in the mother usually indicates serious involvement of the fetus [
         <a href="#rid50">
          50
         </a>
         ]. Labor also tends to be either prolonged or abbreviated, presumably on the basis of maternal uterine muscle involvement [
         <a href="#rid52">
          52,56
         </a>
         ]. (See
         <a class="local">
          'Complications of pregnancy'
         </a>
         below.)
        </p>
        <p>
         Myotonia is not usually present in the first year of life, and electrical myotonia is rare; therefore, the hallmark of congenital DM1 is hypotonia rather than myotonia. Respiratory involvement is common and is the leading cause of death in the neonatal period. It may be so severe that the newborn sustains an asphyxial episode leading to hypoxic brain injury; the encephalopathy is these cases may so dominate the clinical presentation that the underlying myopathy is overlooked [
         <a href="#rid50">
          50
         </a>
         ]. In other cases, neonates with congenital DM1 may be misdiagnosed with hypoxic-ischemic encephalopathy when white matter abnormalities on brain magnetic resonance imaging (MRI), which are commonly seen in DM1, are misattributed to perinatal injury [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
         Mechanical ventilation is required for 70 to 80 percent or more of patients [
         <a href="#rid46">
          46,50
         </a>
         ]. Gastrointestinal (GI) and feeding difficulties are also common, with many children requiring a nasogastric or gastric feeding tube [
         <a href="#rid46">
          46
         </a>
         ]. The feeding difficulties involve both sucking and swallowing and are related to weakness of the facial, masticatory, and pharyngeal muscles. A disturbance of gastric motility, probably related to the smooth muscle involvement in DM1, may play a major role in the feeding difficulties in some infants.
        </p>
        <p>
         With intensive support, most infants survive the neonatal period, but the overall mortality rate is approximately 15 to 20 percent, and approaches 40 percent in severely affected infants [
         <a href="#rid50">
          50
         </a>
         ]. In severely affected infants, cardiomyopathy may be apparent early on and contribute to neonatal death [
         <a href="#rid50">
          50,58
         </a>
         ].
        </p>
        <p>
         In early childhood, there is often a gradual improvement of motor function. Despite this improvement, some degree of hypotonia and facial weakness persists; at age three to five, foot deformities, learning, and behavioral abnormalities present as the main clinical problems [
         <a href="#rid59">
          59
         </a>
         ]. Subsequently, pronounced delays are experienced in motor and mental development, with intellectual disability in 50 to 60 percent of children [
         <a href="#rid55">
          55,59,60
         </a>
         ]. Intelligence quotient (IQ) scores in the 50 to 65 range are common in congenital DM1 patients who survive the neonatal period [
         <a href="#rid50">
          50
         </a>
         ], and the majority of children require assistive services in traditional schools or attend specialized day schools [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
         There appears to be no correlation between the severity of congenital DM at birth and the extent of complications during teenage years [
         <a href="#rid59">
          59
         </a>
         ]. As patients with congenital DM1 age, they develop many of the symptoms and signs of classic, adult-onset DM1, such as the distal predominance of muscle weakness, myotonia, and electrocardiogram (ECG) abnormalities. Those patients who survive early childhood typically experience significant cardiorespiratory morbidity and mortality. Serious cardiac rhythm disturbances may occur as early as the second decade of life in children with the congenital or infantile form of DM1 [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p>
         The CTG repeat size associated with congenital DM1 is usually &gt;1000 [
         <a href="#rid15">
          15
         </a>
         ], though one report noted a few cases with CTG repeat lengths between 730 and 1000 [
         <a href="#rid62">
          62
         </a>
         ]. Inheritance of congenital DM1 is maternal in approximately 90 percent of cases [
         <a href="#rid17">
          17,63,64
         </a>
         ]. This phenomenon stems from the much greater likelihood for anticipation (ie, expansions of CTG repeats) to occur in maternal compared with paternal transmissions. It is not uncommon for an adult (typically the mother) to be diagnosed with DM only after giving birth to an affected neonate, underscoring the potential for subclinical presentation of this disorder.
        </p>
        <p>
         Paternally inherited cases of congenital DM are less common, ranging from 8 to 12 percent of cases in large series [
         <a href="#rid48">
          48,65-69
         </a>
         ]. Whereas mothers of infants with maternally transmitted congenital DM have larger mean trinucleotide (CTG) repeat sizes than mothers of patients with childhood or adult-onset disease [
         <a href="#rid70">
          70
         </a>
         ], fathers of infants with paternally transmitted congenital DM1 have small repeat sizes and/or are asymptomatic at the time of the affected child's birth [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3074915823">
         <span class="h2">
          Childhood DM1
         </span>
         <span class="headingEndMark">
          —
         </span>
         The childhood (infantile) form of DM1 typically presents before the age of 10 years with the involvement of systems and organs other than skeletal muscle. In most cases, the initial manifestations are cognitive and behavioral problems such as intellectual impairment with low IQ, attentional deficits, executive dysfunction, anxiety, and mood disorders [
         <a href="#rid9">
          9,72-75
         </a>
         ]. The CTG repeat size is usually &gt;500 in childhood DM1, although some affected children have a repeat size ≤500 [
         <a href="#rid15">
          15,48,76
         </a>
         ]. Over time, affected children develop muscle symptoms and physical disability that is similar to severe adult-onset classic DM1 [
         <a href="#rid9">
          9,74,75
         </a>
         ].
        </p>
        <p>
         Serious cardiac rhythm disturbances may occur in asymptomatic adolescents with no or only subtle signs of DM [
         <a href="#rid61">
          61
         </a>
         ]. The rate of cardiac conduction abnormalities in childhood DM1 is 15 to 20 percent, most commonly atrioventricular block or incomplete bundle branch block [
         <a href="#rid48">
          48
         </a>
         ]. Sports and physical exercise precipitate arrhythmias in over one-half of these patients. Fewer than 10 percent of patients have clinical evidence of structural heart disease including cardiomyopathy and heart failure [
         <a href="#rid48">
          48,77
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2299022521">
         <span class="h2">
          Classic DM1
         </span>
         <span class="headingEndMark">
          —
         </span>
         The classic form of DM1 becomes symptomatic during the second, third, or fourth decade of life. Major clinical manifestations include (but are not limited to) skeletal and respiratory muscle weakness, myotonia, cataracts, cardiac arrhythmias, and excessive daytime somnolence [
         <a href="#rid9">
          9
         </a>
         ]. In these patients, average lifespan is reduced. The CTG repeat size is generally in the range of 50 to 1000 [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3021812092">
         <span class="h2">
          Mild DM1
         </span>
         <span class="headingEndMark">
          —
         </span>
         The mild (minimal or oligosymptomatic) form of DM1 is characterized by mild weakness, myotonia, and cataracts. Age at onset is between 20 to 70 years, typically after age 40 years, and life expectancy is normal. The CTG repeat size is usually in the range of 50 to 150 [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1273747966">
         <span class="h2">
          DM2
         </span>
         <span class="headingEndMark">
          —
         </span>
         Onset for DM2 ranges from the second to the seventh decades [
         <a href="#rid9">
          9,16
         </a>
         ], often presenting with myotonia (median 30 years), weakness (median 41 years), or cataracts (median 45 years) [
         <a href="#rid16">
          16
         </a>
         ]. In general, DM2 is a less severe disease than classic DM1. In most cases, weakness predominantly involves the proximal muscles, particularly the hip girdle muscles. There is no clear correlation in DM2 between cytosine-cytosine-thymine-guanine (CCTG) repeat size and age of onset or other measures of disease severity.
        </p>
        <p class="headingAnchor" id="H2630427080">
         <span class="h1">
          CLINICAL FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical features of DM at presentation differ according to phenotype (see
         <a class="local">
          'Phenotypes'
         </a>
         above), though most share muscle weakness and myotonia (ie, abnormally slow or delayed muscle relaxation following a normal muscle contraction) as characteristic manifestations.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Skeletal muscle weakness
         </span>
         <span class="headingEndMark">
          —
         </span>
         Skeletal muscle weakness is a characteristic feature of myotonic dystrophy type 1 (DM1) and type 2 (DM2). Differences between DM1 and DM2 with respect to muscle group involvement  (
         <a class="graphic graphic_table graphicRef70688" href="/z/d/graphic/70688.html" rel="external">
          table 4
         </a>
         ) are discussed in the sections that follow.
        </p>
        <p class="headingAnchor" id="H1439555770">
         <span class="h3">
          Weakness in DM1
         </span>
         <span class="headingEndMark">
          —
         </span>
         In DM1, weakness occurs most frequently in facial muscles (levator palpebrae superficialis, temporalis), sternocleidomastoids, distal muscles of the forearm, hand intrinsic muscles (leading to compromised finger dexterity), and ankle dorsiflexors (causing bilateral foot drop) [
         <a href="#rid78">
          78-81
         </a>
         ]. Less commonly, weakness occurs in the quadriceps, respiratory muscles, palatal and pharyngeal muscles, tongue, and extraocular muscles. Muscles of the pelvic girdle, the hamstrings, and ankle plantar flexors are relatively spared in most cases of DM1.
        </p>
        <p>
         Patients with DM1 often have a characteristic facial appearance due to the pattern and longstanding nature of the muscle weakness and wasting. The face is long and narrow, and the palate is high arched. The cheeks are hollowed and the jaw sags. Ptosis and wasting of the sternocleidomastoid muscles are common in DM1 and typically absent in DM2.
        </p>
        <p>
         The natural history of DM1 is that of gradual progression in weakness.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study that followed 50 patients aged 16 to 67 years with DM1, muscle weakness at baseline was symmetrical, with neck flexor and distal muscles weaker than proximal muscle groups [
         <a href="#rid82">
          82
         </a>
         ]. Using manual muscle testing, the average strength decline was approximately 1 percent per year, similar for men and women, and more rapid for distal than proximal muscles (2 to 3 percent for hand grip flexors and 1.2 to 1.6 percent per year for hip flexors).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a series of 158 patients with DM1 who had assessment of finger flexor muscle strength using a hand-held dynamometer, strength diminished at a rate of 1.18 kgN/year for women and 1.61 kgN/year for men [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         As the disease progresses, distal muscles become increasingly weak, and proximal muscles, perhaps spared in the early stages, begin to weaken so that gait and stability slowly deteriorate. Thus, patients with DM1 develop a combination of distal and proximal weakness (foot dorsiflexor weakness, along with knee extensor and hip abductor and flexor weakness) that contributes to an increased incidence of falls. This point is illustrated by the finding that falls and stumbles in patients with DM1 are 10 times more frequent than in a group of healthy volunteers [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2422606215">
         <span class="h3">
          Weakness in DM2
         </span>
         <span class="headingEndMark">
          —
         </span>
         In DM2, neck flexors and finger flexors muscles are affected in the earliest stages [
         <a href="#rid84">
          84
         </a>
         ]. Prior to the identification of its genetic basis, DM2 went by various names, including proximal myotonic myopathy (PROMM) and proximal myotonic dystrophy (PDM) [
         <a href="#rid85">
          85,86
         </a>
         ]. These terms underscore the fact that weakness in the hip girdle region is often the presenting feature of DM2 [
         <a href="#rid16">
          16,87
         </a>
         ]. Weakness of thigh, hip flexor, and extensor muscles frequently impairs the ability to arise from a squat, arise from a chair, or climb stairs [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p>
         Weakness of elbow extensors in DM2 typically develops along with proximal leg weakness. In patients with DM2 over 50 years old, triceps weakness affects approximately 50 percent [
         <a href="#rid16">
          16
         </a>
         ]. Although it is generally symmetrical in distribution, isolated weakness of one triceps has been reported in DM2 [
         <a href="#rid88">
          88
         </a>
         ].
        </p>
        <p>
         Facial weakness may occur in DM2, generally in later stages of the disease, involving approximately 13 percent of patients over age 50 in one study [
         <a href="#rid16">
          16
         </a>
         ]. However, facial weakness is not as prominent in DM2 as it is in DM1. Neck flexor muscle involvement is universal in DM1 and nearly so in DM2 [
         <a href="#rid16">
          16
         </a>
         ]. Weakness of neck flexion and neck extension in DM2 is less severe than in DM1, where a "dropped head posture" is occasionally encountered.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Muscle pain
         </span>
         <span class="headingEndMark">
          —
         </span>
         Muscle pain is a very common symptom in DM1. It does not clearly parallel myotonia and, in fact, it is more common in the legs, where myotonia cannot be demonstrated [
         <a href="#rid89">
          89
         </a>
         ].
        </p>
        <p>
         Most studies have found that pain is also a major complaint and management concern in DM2 [
         <a href="#rid9">
          9,90-93
         </a>
         ]; by contrast, a single-center study of 50 patients with DM2 reported pain symptoms were not common [
         <a href="#rid42">
          42
         </a>
         ]. Pain is one of the symptoms (along with stiffness and fatigue) that can bring patients with DM2 to medical attention before the onset of symptomatic weakness [
         <a href="#rid16">
          16,94
         </a>
         ]. The pain is typically proximal in location, affects the legs more than the arms, is unrelated to myotonia, varies from day to day, and may be problematic at rest. Pain in DM2 may be induced by exercise, palpation, or temperature changes [
         <a href="#rid84">
          84,90,91
         </a>
         ]. Chest pain may trigger a work-up for heart disease.
        </p>
        <p>
         The muscle pain and stiffness of DM2 have been likened to those of fibromyalgia. In one study of 63 randomly selected patients diagnosed with fibromyalgia, the DM2 mutation was identified in two (3 percent) [
         <a href="#rid95">
          95
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Myotonia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Myotonia is a slowed relaxation following a normal muscle contraction. Most patients with DM do not describe symptoms referable to the myotonia (unlike patients with myotonia congenita), and those who do often refer to it as muscle stiffness.
        </p>
        <p>
         Myotonia is most prominent in the early stages of the illness, is aggravated by cold and stress, and is seen most consistently in facial, jaw, tongue, and hand intrinsic muscles [
         <a href="#rid89">
          89
         </a>
         ]. Myotonia is universally present in DM1, whereas myotonia is found in approximately 75 percent of patients with DM2 [
         <a href="#rid16">
          16,94
         </a>
         ]. Myotonia is also more pronounced and relatively more constant in severity in DM1 than DM2. Myotonia varies in DM2, with patients reporting being free of symptoms for days or weeks [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p>
         As a clinical sign, myotonia is often best appreciated in the hand and fingers.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         To elicit grip myotonia, the patient is instructed to grip the examiner's fingers firmly and then to let go rapidly; in the presence of myotonia, the relaxation of the fingers is delayed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         To demonstrate percussion myotonia, the examiner firmly percusses the thenar eminence (specifically the abductor pollicis brevis); in the presence of myotonia, the thumb will abduct and then relax slowly. Alternately, the examiner percusses the extensor digitorum; in the presence of myotonia, the third digit will extend and then relax slowly. Percussion myotonia can be elicited in other muscles as well.
        </p>
        <p>
        </p>
        <p>
         Patients with DM1 (but not DM2) tend to lose clinical myotonia (grip or percussion) as muscle weakness progresses over time.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Cardiac abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         DM1, and possibly DM2, is associated with a significantly increased risk of cardiomyopathy, heart failure, conduction disorders, and arrhythmias [
         <a href="#rid96">
          96
         </a>
         ], which are potential causes of early mortality. Arrhythmias or heart block may occasionally be very early manifestations of DM1, even when neuromuscular symptoms are mild or even unrecognized. While there is some risk of sudden death from cardiac arrhythmias in DM1 [
         <a href="#rid97">
          97-100
         </a>
         ] and DM2 [
         <a href="#rid101">
          101
         </a>
         ], the magnitude of this risk is not easily quantified based on the available data, which consist mainly of small observational studies. (See
         <a class="medical medical_review" href="/z/d/html/5140.html" rel="external">
          "Myotonic dystrophy: Treatment and prognosis", section on 'Life expectancy'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a prospective study of 406 patients with DM1, severe electrocardiogram (ECG) abnormalities were present in 24 percent at baseline [
         <a href="#rid102">
          102
         </a>
         ]. Severe ECG abnormalities were defined as rhythm other than sinus, a PR interval ≥240 msec, QRS duration of ≥120 msec, or second- or third-degree atrioventricular block.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a retrospective multicenter study of 100 patients with DM1, a PR interval &gt;200 msec or a QRS complex duration of &gt;120 msec on ECG were independent predictors of infra-Hisian conduction block [
         <a href="#rid103">
          103
         </a>
         ]. In another study, however, similar ECG parameters were found to have poor predictive value for infra-Hisian conduction delay; thus, electrophysiology testing was recommended for screening of all patients with DM1 to inform the decision regarding prophylactic pacemaker implantation [
         <a href="#rid104">
          104
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a 2021 systematic review of 3677 patients with DM1, the incidence of atrial fibrillation was 10.9 percent [
         <a href="#rid105">
          105
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A population-based study found that the risk of a cardiac conduction disorder for patients with DM was 60 times greater than that of the general population [
         <a href="#rid106">
          106
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Conduction disturbances also affect patients with DM2, although data are sparse. In several small studies, cardiac conduction defects in patients with DM2 were present in 12 to 37 percent [
         <a href="#rid16">
          16,42,107
         </a>
         ].
        </p>
        <p>
         Structural heart abnormalities have also been associated with DM1 and DM2:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a report that evaluated 382 patients with DM1 using transthoracic echocardiography, the following structural abnormalities were noted [
         <a href="#rid77">
          77
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Left ventricular hypertrophy in 20 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Left ventricular dilatation in 19 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Left ventricular systolic dysfunction in 14 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Regional wall motion abnormality in 11 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Left atrial dilatation in 6 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Heart failure was found in 2 percent, based upon clinical history
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among 100 patients with DM2 who were older than 50 years, a history of progressive cardiomyopathy in the absence of myocardial ischemia was found in 7 percent [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of 38 patients with DM2, left ventricular systolic dysfunction was found in 16 percent [
         <a href="#rid107">
          107
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In an autopsy study of four patients with DM2 and sudden death, all had dilated cardiomyopathy, and two had conduction system fibrosis [
         <a href="#rid101">
          101
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Respiratory function
         </span>
         <span class="headingEndMark">
          —
         </span>
         Respiratory complications are common in congenital and classic DM1 and stem from pharyngoesophageal weakness, weakness and myotonia of respiratory muscles, and possibly an alteration of central respiratory drive [
         <a href="#rid108">
          108
         </a>
         ]. Weakness of respiratory muscles leads to a diminution in vital capacity and causes alveolar hypoventilation. Respiratory failure may occur, sometimes precipitated by general anesthesia because of heightened sensitivity to sedatives, anesthetics, and neuromuscular blocking agents [
         <a href="#rid109">
          109
         </a>
         ].
        </p>
        <p>
         Respiratory muscle weakness is rare in patients with DM2 [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Sleep disturbance
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with DM1 often exhibit hypersomnia and excessive daytime sleepiness (EDS) [
         <a href="#rid110">
          110,111
         </a>
         ]. The most likely cause is a central disorder of sleep regulation, rather than sleep fragmentation or a sleep-related disordered breathing [
         <a href="#rid112">
          112,113
         </a>
         ]. The burden of impaired sleep and EDS among patients with DM1 is substantial, with prevalence rates of 33 to 88 percent [
         <a href="#rid114">
          114,115
         </a>
         ]. The wide range of prevalence rates is likely due to methodologic and population differences among studies.
        </p>
        <p>
         While EDS is described in some patients with DM2, it is less severe and far less prevalent than in DM1. In one case-control study, the prevalence of EDS among 29 patients with DM1, 29 with DM2, and 65 population controls was 45, 7, and 6 percent, respectively [
         <a href="#rid116">
          116
         </a>
         ].
        </p>
        <p>
         A distinction should be drawn between EDS associated with DM and the narcolepsy phenotype in which EDS, short sleep latency, and sleep-onset REM are accompanied by sleep paralysis, cataplexy, and hypnagogic and/or hypnopompic hallucinations.
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Endocrine abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         Primary hypogonadism (low-serum testosterone, elevated serum follicle-stimulating hormone [FSH] concentration, oligospermia, and infertility), testicular atrophy, and associated low sperm count with infertility are common problems in DM1 [
         <a href="#rid117">
          117-119
         </a>
         ] and less common in DM2 [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p>
         Insulin hypersecretion is another common finding in patients with DM. It is thought to be a compensatory beta cell response to tissue insulin resistance, and related to the formation of an insulin-resistant receptor because of aberrant regulation of mRNA [
         <a href="#rid89">
          89
         </a>
         ]. In DM1, insulin resistance is present, but frank diabetes is uncommon. The prevalence of diabetes is greater in DM2 [
         <a href="#rid89">
          89
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3128409361">
         <span class="h2">
          Gastrointestinal involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         In DM1, smooth muscle involvement is more common than in other muscular dystrophies and manifests particularly with gastrointestinal (GI) symptoms such as colicky abdominal pain, constipation, diarrhea, and pseudo-obstruction [
         <a href="#rid120">
          120
         </a>
         ]. Irritable bowel-like symptoms (abdominal pain, bloating, and changes in bowel habits) are common in DM1.
        </p>
        <p>
         Upper GI tract involvement is seen in most patients with classic DM1 and leads to dysphagia with resulting aspiration pneumonia, an important cause of morbidity and mortality in DM1. Gallstones also occur in DM1 because of increased tone of the gall bladder sphincter. The presence and severity of GI disturbances in DM1 correlate poorly with the degree of skeletal muscle involvement, and correlate positively with the duration of skeletal muscle disease [
         <a href="#rid121">
          121
         </a>
         ].
        </p>
        <p>
         Although GI symptoms were previously considered uncommon in DM2 [
         <a href="#rid84">
          84
         </a>
         ], a later case-control study that evaluated 29 patients with genetically proven DM2 found that dysphagia for solid food, abdominal pain, and constipation were reported by 41, 62, and 62 percent of patients, respectively [
         <a href="#rid122">
          122
         </a>
         ]. These GI symptoms were significantly more frequent in patients with DM2 than in healthy controls, but were similar to rates found in patients with DM1 [
         <a href="#rid122">
          122
         </a>
         ]. A small companion study that evaluated the subgroup of patients with DM2 and dysphagia found that the dysphagia was relatively mild when assessed with swallowing studies [
         <a href="#rid123">
          123
         </a>
         ]. In addition, no patient with DM2 and dysphagia had a history of aspiration pneumonia or weight loss.
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h2">
          Cognitive impairment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neonates with DM1 develop cognitive dysfunction in a pattern consistent with intellectual disability [
         <a href="#rid60">
          60
         </a>
         ]. (See
         <a class="local">
          'Congenital DM1'
         </a>
         above.)
        </p>
        <p>
         Intellectual disability is a prominent feature of the congenital and childhood (juvenile) forms of DM1 and is often associated with generalized atrophy on magnetic resonance imaging (MRI) studies. Intellectual disability is rare in DM2 [
         <a href="#rid84">
          84
         </a>
         ]. In general, for patients with DM1, the IQ decreases with younger age of onset. In addition, lower IQ has been correlated with longer CTG expansions, mainly related to maternal inheritance [
         <a href="#rid124">
          124
         </a>
         ].
        </p>
        <p>
         There is also evidence for subtle cognitive impairment in patients with classic DM1 and DM2, particularly involving executive and visual-spatial dysfunction [
         <a href="#rid60">
          60,125-127
         </a>
         ]. Even patients with IQ scores in the normal range may show impairment in executive function and abnormalities in visual perception, constructional ability, and visual memory [
         <a href="#rid124">
          124
         </a>
         ]. Furthermore, patients with DM1 have been described with personality and behavioral disturbances [
         <a href="#rid124">
          124
         </a>
         ]. However, the involvement in DM2 appears to be considerably less than in DM1.
        </p>
        <p>
         In both classic DM1 and DM2, frontal lobe cognitive impairment (attention deficits) worsens over time, but does not extend to other areas of cognition [
         <a href="#rid128">
          128
         </a>
         ]. Thus, cognitive problems do not show the same degree of deterioration over time that is typical of muscle dysfunction in DM1.
        </p>
        <p class="headingAnchor" id="H196509146">
         <span class="h2">
          Other features
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of other systemic features are associated with DM1 or DM2 [
         <a href="#rid9">
          9,17
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cataracts occur in almost all patients with DM1 and in a majority of patients with DM2.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hearing impairment is common in patients with DM1 and DM2. In one study, mild to moderate sensorineural hearing loss localizing to the cochlea was present in approximately half of adults with DM2 [
         <a href="#rid129">
          129
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Premature frontal balding can affect men and women with DM1 but is uncommon in DM2.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Creatine kinase concentration may be mildly to moderately elevated in both DM1 and DM2.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abnormal liver function tests are frequent in DM1 and DM2, with modestly elevated levels of aminotransferases, alkaline phosphatase, and gamma-glutamyl transpeptidase [
         <a href="#rid130">
          130,131
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum immunoglobulin studies will typically disclose immunoglobulin G (IgG) and immunoglobulin M (IgM) hypogammaglobulinemia in both DM1 and DM2 [
         <a href="#rid89">
          89
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Several reports suggest that patients with DM can develop an axonal sensorimotor polyneuropathy [
         <a href="#rid132">
          132,133
         </a>
         ], and that this manifestation is independent of underlying glucose intolerance [
         <a href="#rid134">
          134
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H191953850">
         <span class="h2">
          Cancer susceptibility
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mounting evidence suggests that DM is associated with an increased risk of cancer. The largest study evaluated data from the Swedish and Danish registries that included 1658 patients with myotonic muscular dystrophy [
         <a href="#rid135">
          135
         </a>
         ]. In 14,170 patient-years of follow-up, the number of DM cases who developed cancer was twofold higher than expected (104 versus 52 expected, standardized incidence ratio 2.0 [95% CI 1.6-2.4]). In particular, significantly elevated risk was found for cancers of the endometrium, brain, ovary, and colon.
        </p>
        <p>
         A number of earlier case reports also suggested that DM is associated with an increased risk of neoplasms, mainly for pilomatricoma (a benign calcifying skin tumor associated with hair follicles), and multiple basal cell carcinomas of the skin [
         <a href="#rid136">
          136
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h2">
          Neuroimaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Brain MRI studies in patients with DM1 demonstrate abnormalities in the frontal and anterior portion of the temporal lobes, including cortical atrophy and subcortical white matter hyperintense lesions  (
         <a class="graphic graphic_diagnosticimage graphicRef54809" href="/z/d/graphic/54809.html" rel="external">
          image 1
         </a>
         ) [
         <a href="#rid137">
          137
         </a>
         ]. Ventriculomegaly and white matter abnormalities are commonly seen in congenital DM1 and may be detected prenatally on fetal MRI [
         <a href="#rid57">
          57
         </a>
         ]. In a longitudinal MRI study of 33 patients with DM1, white matter lesions were noted in 49 percent; other findings included ventriculomegaly, global cortical atrophy, and a decrease in the volume of deep gray matter structures [
         <a href="#rid138">
          138
         </a>
         ]. The white and gray matter involvement was progressive with associated decline in cognitive function over time, suggesting a neurodegenerative process.
        </p>
        <p>
         In patients with DM1, and to a limited degree in DM2, positron emission tomography (PET) studies demonstrate hypoperfusion of frontal and temporal lobes, a finding that might underlie the executive dysfunction seen primarily in DM1 and to a lesser extent in DM2 [
         <a href="#rid139">
          139
         </a>
         ]. Limited MRI data suggest that patients with DM2 develop loss of gray matter involving the brainstem, hypothalamic and thalamic regions, and white matter mainly involving the corpus callosum [
         <a href="#rid140">
          140
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1139303401">
         <span class="h2">
          Muscle biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Muscle biopsy in DM1 and DM2 is notable for pathologic alterations, including a marked increase of internalized nuclei (arrayed in chains in longitudinal section), severely atrophic muscle fibers with pyknotic nuclear clumps, muscle fiber necrosis and regeneration of isolated muscle fibers, architectural changes such as sarcoplasmic masses and ring fibers, and a preferential atrophy of type I fibers [
         <a href="#rid16">
          16,141
         </a>
         ]. Examples of muscle biopsy specimens from patients with DM are available online from the Washington University (St. Louis, MO)
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fneuromuscular.wustl.edu%2Fpathol%2Fmyotdyspath.htm&amp;token=aymqKW0TxpuRnr5Kk2i5DrPs9R1pVEwnzMnHlRvOkCnywevD6wN%2FDJtEPf872Mgwde29f11SlAkgvExLX3fZng%3D%3D&amp;TOPIC_ID=5147" target="_blank">
          Neuromuscular Disease Center
         </a>
         .
        </p>
        <p class="headingAnchor" id="H2739043736">
         <span class="h2">
          Complications of pregnancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Complications of pregnancy may be seen in both DM1 and DM2.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study and literature review of DM1, preterm labor before 34 weeks occurred in 19 percent of gestations and was often but not exclusively attributed to congenitally affected fetuses [
         <a href="#rid142">
          142
         </a>
         ]. There were an increased number of operative deliveries because of prolonged labor, with a cesarean delivery rate of 36 percent. Ectopic pregnancy occurred in 4 percent, and placenta previa in 9 percent of gestations. Postpartum hemorrhage due to uterine atonia was a rare event.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of 96 pregnancies involving 42 women with DM2, early and late miscarriages occurred in 13 and 4 percent, respectively [
         <a href="#rid143">
          143
         </a>
         ]. Preterm labor occurred in 50 percent of pregnancies, resulting in 27 percent preterm deliveries in women with overt DM2 in pregnancy.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the vast majority of patients with myotonic dystrophy type 1 (DM1) or typical type 2 (DM2), the diagnosis can be made clinically and confirmed with genetic testing.
        </p>
        <p>
         The diagnostic process begins with the clinical impression that DM might account for the presenting symptoms and signs. Typically, patients with DM1 come to medical attention because of intellectual disability or severe muscle weakness and myotonia, whereas patients with DM2 usually present with muscle pain, stiffness, fatigue, or proximal muscle weakness [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
         The clinical diagnosis of one of the DMs can be readily established when there is muscle weakness and clinical myotonia in the setting of a positive family history. A family history of affected neonates (congenital DM) points to the diagnosis of DM1, as does a distribution of weakness that includes the neck, face, and distal muscles with relative sparing of the proximal muscles. Prominent early involvement of neck flexors, finger flexors, and, later, hip girdle muscles and sparing facial and hand intrinsic muscles, should suggest the diagnosis of DM2.
        </p>
        <p>
         Because genetic testing is the gold standard for confirming the diagnosis of DM1 and DM2, the diagnostic role of electromyography (EMG) is limited. However, it is still important in atypical cases where the detection of myotonia provides support for the diagnosis of DM. EMG is also used when molecular testing for DM1 or DM2 is normal. In such cases, the demonstration of electrical myotonia supports the alternative diagnosis of a channelopathy, such as myotonia congenita, paramyotonia, and hyperkalemic periodic paralysis.
        </p>
        <p>
         In some instances, the diagnosis may be challenging for both DM1 and DM2. As an example, patients may present with muscle pain and/or mild to moderate elevations in serum creatine kinase, or with an extramuscular manifestation of DM in the absence of significant muscle weakness or a family history [
         <a href="#rid88">
          88,144
         </a>
         ]. In such circumstances, a high index of suspicion for a DM is required so that appropriate testing can be carried out and the diagnosis established.
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          Genetic testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Specific genetic testing to demonstrate the presence of an expanded cytosine-thymine-guanine (CTG) repeat in the dystrophia myotonica protein kinase (
         <em>
          DMPK
         </em>
         ) gene is the gold standard for the diagnosis of DM1. Normal
         <em>
          DMPK
         </em>
         gene alleles contain 5 to 34 CTG repeats. Mutable normal alleles (premutation alleles) contain 35 to 49 repeats. Children of individuals with the premutation are at increased risk of inheriting a larger repeat size and having symptoms. Full penetrance alleles of ≥50 CTG repeats are associated with disease manifestations. (See
         <a class="local">
          'Genetics'
         </a>
         above.)
        </p>
        <p>
         Specific genetic testing for the cytosine-cytosine-thymine-guanine (CCTG) repeat in the
         <em>
          ZNF9
         </em>
         (
         <em>
          CNBP
         </em>
         ) gene is appropriate if DM1 testing is negative and the clinical suspicion of DM is high. DM2 is caused by a single mutational mechanism, a CCTG tetranucleotide expansion of ≥75 repeats (up to 11,000 repeats). (See
         <a class="local">
          'Genetics'
         </a>
         above.)
        </p>
        <p>
         A high-throughput screening technique based on melt curve analysis seems to detect expanded CTG repeats readily and is adaptable to large-scale testing programs like newborn screening [
         <a href="#rid33">
          33,145
         </a>
         ]. Traditional methods used to detect the expanded CTG repeats include Southern blot or triplet-primed PCR, but they are technically challenging and not suited for newborn screening or population studies [
         <a href="#rid145">
          145
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h2">
          Electromyography
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is appropriate to begin the confirmatory testing for DM1 and DM2 with genetic analysis and omit electrodiagnostic studies when there is a strong clinical suspicion for the diagnosis of DM. However, EMG is still an important test in the evaluation of select patients suspected of having a myopathic disorder, such as one of the DMs. It is useful for demonstrating the presence of myotonia if this has not been found clinically or if uncertainty persists regarding its presence or absence on examination.
        </p>
        <p>
         Electrical myotonia typically consists of repetitive discharges of muscle fiber action potentials at 20 to 80 Hz that wax and wane in amplitude and frequency, producing a sound often reminiscent of a dive bomber or a motorcycle engine when audio-amplified. (See
         <a class="medical medical_review" href="/z/d/html/5145.html" rel="external">
          "Overview of electromyography", section on 'Myotonic discharges'
         </a>
         .)
        </p>
        <p>
         Not every muscle will show evidence for myotonia, so a thorough EMG examination should include evaluation of multiple distal arm and facial muscles. Myotonia is generally easier to elicit in DM1 than DM2 [
         <a href="#rid146">
          146
         </a>
         ]. In DM1, it tends to be waxing-waning (ie, classic discharges that increase and decrease in both amplitude and frequency), whereas in DM2 it tends to be waning (ie, discharges that gradually decrease in frequency or amplitude). The most distal muscles (the tibialis anterior and first dorsal interosseous) are most likely to have myotonic discharge in both disorders. The severity of myotonia correlates with muscle weakness in DM1, but not in DM2 [
         <a href="#rid146">
          146
         </a>
         ]. In occasional instances of DM2, neither clinical nor electrical myotonia can be demonstrated [
         <a href="#rid88">
          88,144,147
         </a>
         ].
        </p>
        <p>
         Electrical myotonia may also be encountered in nondystrophic myopathies [
         <a href="#rid148">
          148
         </a>
         ]. These include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Myotonia congenita
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hyperkalemic periodic paralysis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Paramyotonia congenita
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adult-onset acid maltase deficiency
        </p>
        <p>
        </p>
        <p>
         Myotonia is present uncommonly in a number of other conditions, including chronic denervating disorders, polymyositis, inclusion body myositis, and toxic myopathies (eg, associated with statins, clofibrate,
         <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">
          chloroquine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h2">
          Other investigations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Slit lamp examination may reveal the characteristic posterior subcapsular cataracts, which are detectable as red and green iridescent opacities. Electrocardiography (ECG) is critically important for the recognition and characterization of asymptomatic cardiac conduction defects that are often encountered in DM1 and DM2 and require vigilant monitoring. (See
         <a class="local">
          'Cardiac abnormalities'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5140.html" rel="external">
          "Myotonic dystrophy: Treatment and prognosis", section on 'Cardiac disturbances'
         </a>
         .)
        </p>
        <p>
         The diagnostic role for muscle biopsy is limited, given the availability of genetic testing for DM1 or DM2. However, muscle biopsy may be useful to help distinguish DM2 from an inflammatory or metabolic myopathy when they cannot be differentiated by clinical presentation alone. Muscle biopsy may suggest the diagnosis of DM in atypical cases with minimal weakness, unexplained elevations in creatine kinase, and nonspecific EMG findings [
         <a href="#rid88">
          88,144
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2525972391">
         <span class="h2">
          Differential diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         DM1 and DM2 are the only known hereditary causes of multisystem DMs. Additional evaluation with EMG, serum creatine kinase level, and/or muscle biopsy may be needed to look for other causes of muscle disease if molecular genetic testing excludes DM1 and DM2 [
         <a href="#rid81">
          81
         </a>
         ].
        </p>
        <p>
         The differential diagnosis for hereditary distal myopathies (without myotonia) includes a number of distal muscular dystrophies/myopathies  (
         <a class="graphic graphic_table graphicRef51980" href="/z/d/graphic/51980.html" rel="external">
          table 5
         </a>
         ), such as [
         <a href="#rid81">
          81
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hereditary inclusion body myopathy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Welander distal myopathy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Limb-girdle muscular dystrophy (LGMD) types R2 (dysferlinopathy) and R12 (anoctamin 5-related) (see
         <a class="medical medical_review" href="/z/d/html/6190.html" rel="external">
          "Limb-girdle muscular dystrophy"
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Besides lacking myotonia, these disorders can be distinguished from DM1 and DM2 based upon clinical features, muscle biopsy findings, and molecular genetic testing  (
         <a class="graphic graphic_table graphicRef51980" href="/z/d/graphic/51980.html" rel="external">
          table 5
         </a>
         ).
        </p>
        <p>
         Although rarely confused with DM, electrical myotonia may be encountered in a number of nondystrophic myopathies. (See
         <a class="local">
          'Electromyography'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3994807507">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/121073.html" rel="external">
          "Society guideline links: Muscular dystrophy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H27">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15489.html" rel="external">
          "Patient education: Muscular dystrophy (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/725.html" rel="external">
          "Patient education: Overview of muscular dystrophies (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H28">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Description
         </strong>
         – Myotonic dystrophy type 1 (DM1) and type 2 (DM2) are multisystem disorders characterized by skeletal muscle weakness and myotonia  (
         <a class="graphic graphic_table graphicRef75472" href="/z/d/graphic/75472.html" rel="external">
          table 1
         </a>
         ), cardiac conduction abnormalities, cataracts, and other abnormalities  (
         <a class="graphic graphic_table graphicRef51888" href="/z/d/graphic/51888.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Phenotypes'
         </a>
         above and
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetics
         </strong>
         – DM1 results from an expansion of a cytosine-thymine-guanine (CTG) trinucleotide repeat in the 3'-untranslated region of the dystrophia myotonica protein kinase (
         <em>
          DMPK
         </em>
         ) gene. DM2 is caused by an expansion of a cytosine-cytosine-thymine-guanine (CCTG) tetranucleotide repeat located in intron 1 of the
         <em>
          ZNF9
         </em>
         (
         <em>
          CNBP
         </em>
         ) gene. (See
         <a class="local">
          'Genetics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathophysiology
         </strong>
         – Although the pathophysiology of DM is incompletely understood, the mechanism appears to involve RNA toxicity that results from the expanded repeat in the transcripts from the mutant DM alleles  (
         <a class="graphic graphic_figure graphicRef77706" href="/z/d/graphic/77706.html" rel="external">
          figure 1
         </a>
         ). (See
         <a class="local">
          'Pathophysiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – DM is the most common muscular dystrophy among adults of European ancestry. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features and phenotypes
         </strong>
         – The clinical features of DM at presentation differ according to phenotype, though most phenotypes share muscle weakness and myotonia. In general, the severity of the DM1 phenotype correlates loosely with the cytosine-thymine-guanine (CTG) repeat size  (
         <a class="graphic graphic_table graphicRef110272" href="/z/d/graphic/110272.html" rel="external">
          table 3
         </a>
         ), but there is considerable variability and overlap between phenotypes (see
         <a class="local">
          'Phenotypes'
         </a>
         above and
         <a class="local">
          'Clinical features'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Congenital DM1
         </strong>
         – The congenital form of DM1 is characterized by hypotonia, poor feeding, and respiratory failure, which is the leading cause of death in the neonatal period. (See
         <a class="local">
          'Congenital DM1'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Childhood DM1
         </strong>
         – The childhood form of DM1 typically presents before the age of 10 years. In most cases, the initial manifestations are cognitive and behavioral problems. Over time, affected children develop muscle symptoms and disability that is similar to severe adult-onset classic DM1. (See
         <a class="local">
          'Childhood DM1'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Classic DM1
         </strong>
         – The classic form of DM1 becomes symptomatic during the second, third, or fourth decade of life. Major clinical manifestations include (but are not limited to) skeletal and respiratory muscle weakness, myotonia, cataracts, cardiac arrhythmias, and excessive daytime sleepiness (EDS). Average lifespan is reduced. (See
         <a class="local">
          'Classic DM1'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Mild DM1
         </strong>
         – The mild form of DM1 is characterized by mild weakness, myotonia, or cataracts. The age at onset is between 20 to 70 years, though onset is usually after age 40 years. Life expectancy is normal. (See
         <a class="local">
          'Mild DM1'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          DM2
         </strong>
         – The onset of DM2 ranges from the second to the seventh decades, and the condition often presents with myotonia, weakness, or cataracts. In most cases, proximal muscle weakness predominates, particularly involving the hip girdle muscles. In general, DM2 is a less severe disease than classic DM1  (
         <a class="graphic graphic_table graphicRef70688" href="/z/d/graphic/70688.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="local">
          'DM2'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation and diagnosis
         </strong>
         – The diagnosis of DM can usually be made clinically in a patient with the characteristic presentation and a positive family history. Genetic testing for an expanded CTG repeat in the
         <em>
          DMPK
         </em>
         gene is the gold standard for confirming the diagnosis of DM1. Testing for the CCTG repeat in the
         <em>
          ZNF9
         </em>
         gene is appropriate if DM1 testing is negative. Electromyography (EMG) will usually demonstrate the presence of myotonia if this has not been found clinically or if uncertainty persists regarding its presence or absence on examination. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – The differential diagnosis for hereditary distal myopathies (without myotonia) includes a number of distal muscular dystrophies/myopathies  (
         <a class="graphic graphic_table graphicRef51980" href="/z/d/graphic/51980.html" rel="external">
          table 5
         </a>
         ), such as hereditary inclusion body myopathy, Welander distal myopathy, and limb-girdle muscular dystrophy (LGMD) types R2 and R12. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – There is no disease-modifying therapy available for the treatment of DM. Management is symptomatic, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5140.html" rel="external">
          "Myotonic dystrophy: Treatment and prognosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3684306517">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges David A Chad, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Brook JD, McCurrach ME, Harley HG, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell 1992; 68:799.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buxton J, Shelbourne P, Davies J, et al. Detection of an unstable fragment of DNA specific to individuals with myotonic dystrophy. Nature 1992; 355:547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fu YH, Pizzuti A, Fenwick RG Jr, et al. An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science 1992; 255:1256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harley HG, Brook JD, Rundle SA, et al. Expansion of an unstable DNA region and phenotypic variation in myotonic dystrophy. Nature 1992; 355:545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahadevan M, Tsilfidis C, Sabourin L, et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 3' untranslated region of the gene. Science 1992; 255:1253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liquori CL, Ricker K, Moseley ML, et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 2001; 293:864.
          </a>
         </li>
         <li class="breakAll">
          Dalton JC, Ranum LPW, Day JW. Myotonic dystrophy type 2. GeneReviews. www.ncbi.nlm.nih.gov/books/NBK1466/ (Accessed on October 17, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamshere MG, Harley H, Harper P, et al. Myotonic dystrophy: the correlation of (CTG) repeat length in leucocytes with age at onset is significant only for patients with small expansions. J Med Genet 1999; 36:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Udd B, Krahe R. The myotonic dystrophies: molecular, clinical, and therapeutic challenges. Lancet Neurol 2012; 11:891.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Puymirat J, Giguère Y, Mathieu J, Bouchard JP. Intergenerational contraction of the CTG repeats in 2 families with myotonic dystrophy type 1. Neurology 2009; 73:2126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pearson CE, Nichol Edamura K, Cleary JD. Repeat instability: mechanisms of dynamic mutations. Nat Rev Genet 2005; 6:729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ashizawa T, Dubel JR, Harati Y. Somatic instability of CTG repeat in myotonic dystrophy. Neurology 1993; 43:2674.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thornton CA, Johnson K, Moxley RT 3rd. Myotonic dystrophy patients have larger CTG expansions in skeletal muscle than in leukocytes. Ann Neurol 1994; 35:104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morales F, Couto JM, Higham CF, et al. Somatic instability of the expanded CTG triplet repeat in myotonic dystrophy type 1 is a heritable quantitative trait and modifier of disease severity. Hum Mol Genet 2012; 21:3558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turner C, Hilton-Jones D. Myotonic dystrophy: diagnosis, management and new therapies. Curr Opin Neurol 2014; 27:599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Day JW, Ricker K, Jacobsen JF, et al. Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology 2003; 60:657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thornton CA. Myotonic dystrophy. Neurol Clin 2014; 32:705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cho DH, Tapscott SJ. Myotonic dystrophy: emerging mechanisms for DM1 and DM2. Biochim Biophys Acta 2007; 1772:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee JE, Cooper TA. Pathogenic mechanisms of myotonic dystrophy. Biochem Soc Trans 2009; 37:1281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kino Y, Washizu C, Oma Y, et al. MBNL and CELF proteins regulate alternative splicing of the skeletal muscle chloride channel CLCN1. Nucleic Acids Res 2009; 37:6477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cooper TA. A reversal of misfortune for myotonic dystrophy? N Engl J Med 2006; 355:1825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fugier C, Klein AF, Hammer C, et al. Misregulated alternative splicing of BIN1 is associated with T tubule alterations and muscle weakness in myotonic dystrophy. Nat Med 2011; 17:720.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charlet-B N, Savkur RS, Singh G, et al. Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing. Mol Cell 2002; 10:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Savkur RS, Philips AV, Cooper TA. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet 2001; 29:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Philips AV, Timchenko LT, Cooper TA. Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. Science 1998; 280:737.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berg J, Jiang H, Thornton CA, Cannon SC. Truncated ClC-1 mRNA in myotonic dystrophy exerts a dominant-negative effect on the Cl current. Neurology 2004; 63:2371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wheeler TM, Lueck JD, Swanson MS, et al. Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. J Clin Invest 2007; 117:3952.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yadava RS, Frenzel-McCardell CD, Yu Q, et al. RNA toxicity in myotonic muscular dystrophy induces NKX2-5 expression. Nat Genet 2008; 40:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakamori M, Kimura T, Kubota T, et al. Aberrantly spliced alpha-dystrobrevin alters alpha-syntrophin binding in myotonic dystrophy type 1. Neurology 2008; 70:677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Magee A, Nevin NC. The epidemiology of myotonic dystrophy in Northern Ireland. Community Genet 1999; 2:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siciliano G, Manca M, Gennarelli M, et al. Epidemiology of myotonic dystrophy in Italy: re-apprisal after genetic diagnosis. Clin Genet 2001; 59:344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Norwood FL, Harling C, Chinnery PF, et al. Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. Brain 2009; 132:3175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson NE, Butterfield RJ, Mayne K, et al. Population-Based Prevalence of Myotonic Dystrophy Type 1 Using Genetic Analysis of Statewide Blood Screening Program. Neurology 2021; 96:e1045.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yotova V, Labuda D, Zietkiewicz E, et al. Anatomy of a founder effect: myotonic dystrophy in Northeastern Quebec. Hum Genet 2005; 117:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           López de Munain A, Blanco A, Emparanza JI, et al. Prevalence of myotonic dystrophy in Guipúzcoa (Basque Country, Spain). Neurology 1993; 43:1573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lotz BP, van der Meyden CH. Myotonic dystrophy. Part I. A genealogical study in the northern Transvaal. S Afr Med J 1985; 67:812.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ashizawa T, Epstein HF. Ethnic distribution of myotonic dystrophy gene. Lancet 1991; 338:642.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsiao KM, Chen SS, Li SY, et al. Epidemiological and genetic studies of myotonic dystrophy type 1 in Taiwan. Neuroepidemiology 2003; 22:283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldman A, Ramsay M, Jenkins T. Ethnicity and myotonic dystrophy: a possible explanation for its absence in sub-Saharan Africa. Ann Hum Genet 1996; 60:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suominen T, Bachinski LL, Auvinen S, et al. Population frequency of myotonic dystrophy: higher than expected frequency of myotonic dystrophy type 2 (DM2) mutation in Finland. Eur J Hum Genet 2011; 19:776.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Udd B, Meola G, Krahe R, et al. 140th ENMC International Workshop: Myotonic Dystrophy DM2/PROMM and other myotonic dystrophies with guidelines on management. Neuromuscul Disord 2006; 16:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roy B, Wu Q, Whitaker CH, Felice KJ. Myotonic Muscular Dystrophy Type 2 in CT, USA: A Single-Center Experience With 50 Patients. J Clin Neuromuscul Dis 2021; 22:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wesström G, Bensch J, Schollin J. Congenital myotonic dystrophy. Incidence, clinical aspects and early prognosis. Acta Paediatr Scand 1986; 75:849.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           González de Dios J, Martínez Frías ML, Egües Jimeno J, et al. [Epidemiological study of Steinert's congenital myotonic dystrophy: dysmorphological characteristics]. An Esp Pediatr 1999; 51:389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Darin N, Tulinius M. Neuromuscular disorders in childhood: a descriptive epidemiological study from western Sweden. Neuromuscul Disord 2000; 10:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campbell C, Levin S, Siu VM, et al. Congenital myotonic dystrophy: Canadian population-based surveillance study. J Pediatr 2013; 163:120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arsenault ME, Prévost C, Lescault A, et al. Clinical characteristics of myotonic dystrophy type 1 patients with small CTG expansions. Neurology 2006; 66:1248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lagrue E, Dogan C, De Antonio M, et al. A large multicenter study of pediatric myotonic dystrophy type 1 for evidence-based management. Neurology 2019; 92:e852.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaki M, Boyd PA, Impey L, et al. Congenital myotonic dystrophy: prenatal ultrasound findings and pregnancy outcome. Ultrasound Obstet Gynecol 2007; 29:284.
          </a>
         </li>
         <li class="breakAll">
          Darras BT, Volpe JJ. Muscle involvement and restricted disorders. In: Volpe's Neurology of the Newborn, 6th ed, Volpe JJ, Inder TE, Darras BT, et al (Eds), Elsevier, Philadephia 2017. p.922.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pearse RG, Höweler CJ. Neonatal form of dystrophia myotonica. Five cases in preterm babies and a review of earlier reports. Arch Dis Child 1979; 54:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shore RN, MacLachlan TB. Pregnancy with myotonic dystrophy: course, complications and management. Obstet Gynecol 1971; 38:448.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunn LJ, Dierker LI. Recurrent hydramnios in association with myotonia dystrophica. Obstet Gynecol 1973; 42:104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moosa A. The feeding difficulty in infantile myotonic dystrophy. Dev Med Child Neurol 1974; 16:824.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hageman AT, Gabreëls FJ, Liem KD, et al. Congenital myotonic dystrophy; a report on thirteen cases and a review of the literature. J Neurol Sci 1993; 115:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sarnat HB, O'Connor T, Byrne PA. Clinical effects of myotonic dystrophy on pregnancy and the neonate. Arch Neurol 1976; 33:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peglar LM, Nagaraj UD, Tian C, Venkatesan C. White Matter Lesions Detected by Magnetic Resonance Imaging in Neonates and Children With Congenital Myotonic Dystrophy. Pediatr Neurol 2019; 96:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Igarashi H, Momoi MY, Yamagata T, et al. Hypertrophic cardiomyopathy in congenital myotonic dystrophy. Pediatr Neurol 1998; 18:366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roig M, Balliu PR, Navarro C, et al. Presentation, clinical course, and outcome of the congenital form of myotonic dystrophy. Pediatr Neurol 1994; 11:208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Modoni A, Silvestri G, Pomponi MG, et al. Characterization of the pattern of cognitive impairment in myotonic dystrophy type 1. Arch Neurol 2004; 61:1943.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bassez G, Lazarus A, Desguerre I, et al. Severe cardiac arrhythmias in young patients with myotonic dystrophy type 1. Neurology 2004; 63:1939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Redman JB, Fenwick RG Jr, Fu YH, et al. Relationship between parental trinucleotide GCT repeat length and severity of myotonic dystrophy in offspring. JAMA 1993; 269:1960.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsilfidis C, MacKenzie AE, Mettler G, et al. Correlation between CTG trinucleotide repeat length and frequency of severe congenital myotonic dystrophy. Nat Genet 1992; 1:192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Temmerman N, Sermon K, Seneca S, et al. Intergenerational instability of the expanded CTG repeat in the DMPK gene: studies in human gametes and preimplantation embryos. Am J Hum Genet 2004; 75:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakagawa M, Yamada H, Higuchi I, et al. A case of paternally inherited congenital myotonic dystrophy. J Med Genet 1994; 31:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ohya K, Tachi N, Chiba S, et al. Congenital myotonic dystrophy transmitted from an asymptomatic father with a DM-specific gene. Neurology 1994; 44:1958.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tachi N, Ohya K, Yamagata H, et al. Haplotype analysis of congenital myotonic dystrophy patients from asymptomatic DM father. Pediatr Neurol 1997; 16:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Die-Smulders CE, Smeets HJ, Loots W, et al. Paternal transmission of congenital myotonic dystrophy. J Med Genet 1997; 34:930.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tanaka Y, Suzuki Y, Shimozawa N, et al. Congenital myotonic dystrophy: report of paternal transmission. Brain Dev 2000; 22:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harley HG, Rundle SA, MacMillan JC, et al. Size of the unstable CTG repeat sequence in relation to phenotype and parental transmission in myotonic dystrophy. Am J Hum Genet 1993; 52:1164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zeesman S, Carson N, Whelan DT. Paternal transmission of the congenital form of myotonic dystrophy type 1: a new case and review of the literature. Am J Med Genet 2002; 107:222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ekström AB, Hakenäs-Plate L, Tulinius M, Wentz E. Cognition and adaptive skills in myotonic dystrophy type 1: a study of 55 individuals with congenital and childhood forms. Dev Med Child Neurol 2009; 51:982.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Douniol M, Jacquette A, Cohen D, et al. Psychiatric and cognitive phenotype of childhood myotonic dystrophy type 1. Dev Med Child Neurol 2012; 54:905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Angeard N, Jacquette A, Gargiulo M, et al. A new window on neurocognitive dysfunction in the childhood form of myotonic dystrophy type 1 (DM1). Neuromuscul Disord 2011; 21:468.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Echenne B, Rideau A, Roubertie A, et al. Myotonic dystrophy type I in childhood Long-term evolution in patients surviving the neonatal period. Eur J Paediatr Neurol 2008; 12:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ho G, Cardamone M, Farrar M. Congenital and childhood myotonic dystrophy: Current aspects of disease and future directions. World J Clin Pediatr 2015; 4:66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhakta D, Lowe MR, Groh WJ. Prevalence of structural cardiac abnormalities in patients with myotonic dystrophy type I. Am Heart J 2004; 147:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Avaria M, Patterson V. Myotonic dystrophy: relative sensitivity of symptoms signs and abnormal investigations. Ulster Med J 1994; 63:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whittaker RG, Ferenczi E, Hilton-Jones D. Myotonic dystrophy: practical issues relating to assessment of strength. J Neurol Neurosurg Psychiatry 2006; 77:1282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bouchard JP, Cossette L, Bassez G, Puymirat J. Natural history of skeletal muscle involvement in myotonic dystrophy type 1: a retrospective study in 204 cases. J Neurol 2015; 262:285.
          </a>
         </li>
         <li class="breakAll">
          Bird TD. Myotonic dystrophy type 1. In: GeneReviews [Internet], Adam MP, Ardinger HH, Pagon RA, et al. (Eds), University of Washington, Seattle. Available at: https://www.ncbi.nlm.nih.gov/books/NBK1165/ (Accessed on January 26, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathieu J, Boivin H, Richards CL. Quantitative motor assessment in myotonic dystrophy. Can J Neurol Sci 2003; 30:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wiles CM, Busse ME, Sampson CM, et al. Falls and stumbles in myotonic dystrophy. J Neurol Neurosurg Psychiatry 2006; 77:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meola G, Moxley RT 3rd. Myotonic dystrophy type 2 and related myotonic disorders. J Neurol 2004; 251:1173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ricker K, Koch MC, Lehmann-Horn F, et al. Proximal myotonic myopathy: a new dominant disorder with myotonia, muscle weakness, and cataracts. Neurology 1994; 44:1448.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Udd B, Krahe R, Wallgren-Pettersson C, et al. Proximal myotonic dystrophy--a family with autosomal dominant muscular dystrophy, cataracts, hearing loss and hypogonadism: heterogeneity of proximal myotonic syndromes? Neuromuscul Disord 1997; 7:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papadimas GK, Kekou K, Papadopoulos C, et al. Phenotypic variability and molecular genetics in proximal myotonic myopathy. Muscle Nerve 2015; 51:686.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milone M, Batish SD, Daube JR. Myotonic dystrophy type 2 with focal asymmetric muscle weakness and no electrical myotonia. Muscle Nerve 2009; 39:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Machuca-Tzili L, Brook D, Hilton-Jones D. Clinical and molecular aspects of the myotonic dystrophies: a review. Muscle Nerve 2005; 32:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suokas KI, Haanpää M, Kautiainen H, et al. Pain in patients with myotonic dystrophy type 2: a postal survey in Finland. Muscle Nerve 2012; 45:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           George A, Schneider-Gold C, Zier S, et al. Musculoskeletal pain in patients with myotonic dystrophy type 2. Arch Neurol 2004; 61:1938.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meola G. Myotonic dystrophy type 2: the 2020 update. Acta Myol 2020; 39:222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Vliet J, Tieleman AA, Verrips A, et al. Qualitative and Quantitative Aspects of Pain in Patients With Myotonic Dystrophy Type 2. J Pain 2018; 19:920.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heatwole C, Johnson N, Bode R, et al. Patient-Reported Impact of Symptoms in Myotonic Dystrophy Type 2 (PRISM-2). Neurology 2015; 85:2136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Auvinen S, Suominen T, Hannonen P, et al. Myotonic dystrophy type 2 found in two of sixty-three persons diagnosed as having fibromyalgia. Arthritis Rheum 2008; 58:3627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lund M, Diaz LJ, Ranthe MF, et al. Cardiac involvement in myotonic dystrophy: a nationwide cohort study. Eur Heart J 2014; 35:2158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fragola PV, Luzi M, Calò L, et al. Cardiac involvement in myotonic dystrophy. Am J Cardiol 1994; 74:1070.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Florek RC, Triffon DW, Mann DE, et al. Electrocardiographic abnormalities in patients with myotonic dystrophy. West J Med 1990; 153:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hawley RJ, Milner MR, Gottdiener JS, Cohen A. Myotonic heart disease: a clinical follow-up. Neurology 1991; 41:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Melacini P, Buja G, Fasoli G, et al. The natural history of cardiac involvement in myotonic dystrophy: an eight-year follow-up in 17 patients. Clin Cardiol 1988; 11:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schoser BG, Ricker K, Schneider-Gold C, et al. Sudden cardiac death in myotonic dystrophy type 2. Neurology 2004; 63:2402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Groh WJ, Groh MR, Saha C, et al. Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. N Engl J Med 2008; 358:2688.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joosten IBT, van Lohuizen R, den Uijl DW, et al. Electrocardiographic predictors of infrahissian conduction disturbances in myotonic dystrophy type 1. Europace 2021; 23:298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Creta A, Providência R, Gossios T, et al. A Normal Electrocardiogram Does Not Exclude Infra-Hisian Conduction Disease in Patients With Myotonic Dystrophy Type 1. JACC Clin Electrophysiol 2021; 7:1038.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Russo V, Papa AA, Lioncino M, et al. Prevalence of atrial fibrillation in myotonic dystrophy type 1: A systematic review. Neuromuscul Disord 2021; 31:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson NE, Abbott D, Cannon-Albright LA. Relative risks for comorbidities associated with myotonic dystrophy: A population-based analysis. Muscle Nerve 2015; 52:659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wahbi K, Meune C, Bécane HM, et al. Left ventricular dysfunction and cardiac arrhythmias are frequent in type 2 myotonic dystrophy: a case control study. Neuromuscul Disord 2009; 19:468.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bogaard JM, van der Meché FG, Hendriks I, Ververs C. Pulmonary function and resting breathing pattern in myotonic dystrophy. Lung 1992; 170:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klompe L, Lancé M, van der Woerd D, et al. Anaesthesiological and ventilatory precautions during cardiac surgery in Steinert's disease. J Card Surg 2007; 22:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Culebras A. Sleep and neuromuscular disorders. Neurol Clin 2005; 23:1209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ho G, Widger J, Cardamone M, Farrar MA. Quality of life and excessive daytime sleepiness in children and adolescents with myotonic dystrophy type 1. Sleep Med 2017; 32:92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laberge L, Gagnon C, Dauvilliers Y. Daytime sleepiness and myotonic dystrophy. Curr Neurol Neurosci Rep 2013; 13:340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ono S, Takahashi K, Jinnai K, et al. Loss of serotonin-containing neurons in the raphe of patients with myotonic dystrophy: a quantitative immunohistochemical study and relation to hypersomnia. Neurology 1998; 50:535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laberge L, Bégin P, Montplaisir J, Mathieu J. Sleep complaints in patients with myotonic dystrophy. J Sleep Res 2004; 13:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heatwole C, Bode R, Johnson N, et al. Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1). Neurology 2012; 79:348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tieleman AA, Knoop H, van de Logt AE, et al. Poor sleep quality and fatigue but no excessive daytime sleepiness in myotonic dystrophy type 2. J Neurol Neurosurg Psychiatry 2010; 81:963.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vazquez JA, Pinies JA, Martul P, et al. Hypothalamic-pituitary-testicular function in 70 patients with myotonic dystrophy. J Endocrinol Invest 1990; 13:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ørngreen MC, Arlien-Søborg P, Duno M, et al. Endocrine function in 97 patients with myotonic dystrophy type 1. J Neurol 2012; 259:912.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peric S, Nisic T, Milicev M, et al. Hypogonadism and erectile dysfunction in myotonic dystrophy type 1. Acta Myol 2013; 32:106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rönnblom A, Forsberg H, Danielsson A. Gastrointestinal symptoms in myotonic dystrophy. Scand J Gastroenterol 1996; 31:654.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bellini M, Biagi S, Stasi C, et al. Gastrointestinal manifestations in myotonic muscular dystrophy. World J Gastroenterol 2006; 12:1821.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tieleman AA, van Vliet J, Jansen JB, et al. Gastrointestinal involvement is frequent in Myotonic Dystrophy type 2. Neuromuscul Disord 2008; 18:646.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tieleman AA, Knuijt S, van Vliet J, et al. Dysphagia is present but mild in myotonic dystrophy type 2. Neuromuscul Disord 2009; 19:196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Angelo MG, Bresolin N. Cognitive impairment in neuromuscular disorders. Muscle Nerve 2006; 34:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meola G, Sansone V, Perani D, et al. Reduced cerebral blood flow and impaired visual-spatial function in proximal myotonic myopathy. Neurology 1999; 53:1042.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meola G, Sansone V, Perani D, et al. Executive dysfunction and avoidant personality trait in myotonic dystrophy type 1 (DM-1) and in proximal myotonic myopathy (PROMM/DM-2). Neuromuscul Disord 2003; 13:813.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaul C, Schmidt T, Windisch G, et al. Subtle cognitive dysfunction in adult onset myotonic dystrophy type 1 (DM1) and type 2 (DM2). Neurology 2006; 67:350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sansone V, Gandossini S, Cotelli M, et al. Cognitive impairment in adult myotonic dystrophies: a longitudinal study. Neurol Sci 2007; 28:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Vliet J, Tieleman AA, van Engelen BGM, et al. Hearing impairment in patients with myotonic dystrophy type 2. Neurology 2018; 90:e615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heatwole CR, Miller J, Martens B, Moxley RT 3rd. Laboratory abnormalities in ambulatory patients with myotonic dystrophy type 1. Arch Neurol 2006; 63:1149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Achiron A, Barak Y, Magal N, et al. Abnormal liver test results in myotonic dystrophy. J Clin Gastroenterol 1998; 26:292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Panayiotopoulos CP, Scarpalezos S. Dystrophia myotonica. Peripheral nerve involvement and pathogenetic implications. J Neurol Sci 1976; 27:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Logullo F, Censori B, Danni M, et al. Peripheral neuropathy in myotonic dystrophy: electrophysiological and clinical features. Electromyogr Clin Neurophysiol 1992; 32:515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olson ND, Jou MF, Quast JE, Nuttall FQ. Peripheral neuropathy in myotonic dystrophy. Relation to glucose intolerance. Arch Neurol 1978; 35:741.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gadalla SM, Lund M, Pfeiffer RM, et al. Cancer risk among patients with myotonic muscular dystrophy. JAMA 2011; 306:2480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mueller CM, Hilbert JE, Martens W, et al. Hypothesis: neoplasms in myotonic dystrophy. Cancer Causes Control 2009; 20:2009.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donahue LA, Mangla R, Westesson PL. Neuroimaging in myotonic dystrophy type 1. Neurology 2009; 73:1931.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cabada T, Díaz J, Iridoy M, et al. Longitudinal study in patients with myotonic dystrophy type 1: correlation of brain MRI abnormalities with cognitive performances. Neuroradiology 2021; 63:1019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meola G, Sansone V. Cerebral involvement in myotonic dystrophies. Muscle Nerve 2007; 36:294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minnerop M, Luders E, Specht K, et al. Grey and white matter loss along cerebral midline structures in myotonic dystrophy type 2. J Neurol 2008; 255:1904.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lieberman AP, Fischbeck KH. Triplet repeat expansion in neuromuscular disease. Muscle Nerve 2000; 23:843.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rudnik-Schöneborn S, Zerres K. Outcome in pregnancies complicated by myotonic dystrophy: a study of 31 patients and review of the literature. Eur J Obstet Gynecol Reprod Biol 2004; 114:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rudnik-Schöneborn S, Schneider-Gold C, Raabe U, et al. Outcome and effect of pregnancy in myotonic dystrophy type 2. Neurology 2006; 66:579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merlini L, Sabatelli P, Columbaro M, et al. Hyper-CK-emia as the sole manifestation of myotonic dystrophy type 2. Muscle Nerve 2005; 31:764.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Butterfield RJ, Imburgia C, Mayne K, et al. High throughput screening for expanded CTG repeats in myotonic dystrophy type 1 using melt curve analysis. Mol Genet Genomic Med 2021; 9:e1619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Logigian EL, Ciafaloni E, Quinn LC, et al. Severity, type, and distribution of myotonic discharges are different in type 1 and type 2 myotonic dystrophy. Muscle Nerve 2007; 35:479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young NP, Daube JR, Sorenson EJ, Milone M. Absent, unrecognized, and minimal myotonic discharges in myotonic dystrophy type 2. Muscle Nerve 2010; 41:758.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller TM. Differential diagnosis of myotonic disorders. Muscle Nerve 2008; 37:293.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5147 Version 34.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1310900" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1346924" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Detection of an unstable fragment of DNA specific to individuals with myotonic dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1546326" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : An unstable triplet repeat in a gene related to myotonic muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1346923" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Expansion of an unstable DNA region and phenotypic variation in myotonic dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1546325" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Myotonic dystrophy mutation: an unstable CTG repeat in the 3' untranslated region of the gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11486088" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11486088" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9950368" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Myotonic dystrophy: the correlation of (CTG) repeat length in leucocytes with age at onset is significant only for patients with small expansions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22995693" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : The myotonic dystrophies: molecular, clinical, and therapeutic challenges.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20018643" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Intergenerational contraction of the CTG repeats in 2 families with myotonic dystrophy type 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16205713" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Repeat instability: mechanisms of dynamic mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8255475" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Somatic instability of CTG repeat in myotonic dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8285579" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Myotonic dystrophy patients have larger CTG expansions in skeletal muscle than in leukocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22595968" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Somatic instability of the expanded CTG triplet repeat in myotonic dystrophy type 1 is a heritable quantitative trait and modifier of disease severity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25121518" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Myotonic dystrophy: diagnosis, management and new therapies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12601109" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25037086" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Myotonic dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16876389" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Myotonic dystrophy: emerging mechanisms for DM1 and DM2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19909263" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Pathogenic mechanisms of myotonic dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19720736" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : MBNL and CELF proteins regulate alternative splicing of the skeletal muscle chloride channel CLCN1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17065646" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : A reversal of misfortune for myotonic dystrophy?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21623381" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Misregulated alternative splicing of BIN1 is associated with T tubule alterations and muscle weakness in myotonic dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12150906" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11528389" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9563950" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15623702" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Truncated ClC-1 mRNA in myotonic dystrophy exerts a dominant-negative effect on the Cl current.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18008009" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18084293" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : RNA toxicity in myotonic muscular dystrophy induces NKX2-5 expression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18299519" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Aberrantly spliced alpha-dystrobrevin alters alpha-syntrophin binding in myotonic dystrophy type 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14960839" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : The epidemiology of myotonic dystrophy in Northern Ireland.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11359466" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Epidemiology of myotonic dystrophy in Italy: re-apprisal after genetic diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19767415" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33472919" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Population-Based Prevalence of Myotonic Dystrophy Type 1 Using Genetic Analysis of Statewide Blood Screening Program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15883838" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Anatomy of a founder effect: myotonic dystrophy in Northeastern Quebec.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8351014" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Prevalence of myotonic dystrophy in Guipúzcoa (Basque Country, Spain).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3992413" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Myotonic dystrophy. Part I. A genealogical study in the northern Transvaal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1679186" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Ethnic distribution of myotonic dystrophy gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12902623" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Epidemiological and genetic studies of myotonic dystrophy type 1 in Taiwan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8835099" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Ethnicity and myotonic dystrophy: a possible explanation for its absence in sub-Saharan Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21364698" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Population frequency of myotonic dystrophy: higher than expected frequency of myotonic dystrophy type 2 (DM2) mutation in Finland.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16684600" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : 140th ENMC International Workshop: Myotonic Dystrophy DM2/PROMM and other myotonic dystrophies with guidelines on management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33595997" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Myotonic Muscular Dystrophy Type 2 in CT, USA: A Single-Center Experience With 50 Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3564952" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Congenital myotonic dystrophy. Incidence, clinical aspects and early prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10690232" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : [Epidemiological study of Steinert's congenital myotonic dystrophy: dysmorphological characteristics].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10677857" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Neuromuscular disorders in childhood: a descriptive epidemiological study from western Sweden.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23415617" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Congenital myotonic dystrophy: Canadian population-based surveillance study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16636244" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Clinical characteristics of myotonic dystrophy type 1 patients with small CTG expansions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30659139" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : A large multicenter study of pediatric myotonic dystrophy type 1 for evidence-based management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17238150" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Congenital myotonic dystrophy: prenatal ultrasound findings and pregnancy outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17238150" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Congenital myotonic dystrophy: prenatal ultrasound findings and pregnancy outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/475408" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Neonatal form of dystrophia myotonica. Five cases in preterm babies and a review of earlier reports.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5094326" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Pregnancy with myotonic dystrophy: course, complications and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4578428" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Recurrent hydramnios in association with myotonia dystrophica.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4442664" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : The feeding difficulty in infantile myotonic dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8166775" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Congenital myotonic dystrophy; a report on thirteen cases and a review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/779728" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Clinical effects of myotonic dystrophy on pregnancy and the neonate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31005477" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : White Matter Lesions Detected by Magnetic Resonance Imaging in Neonates and Children With Congenital Myotonic Dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9588538" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Hypertrophic cardiomyopathy in congenital myotonic dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7880334" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Presentation, clinical course, and outcome of the congenital form of myotonic dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15596617" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Characterization of the pattern of cognitive impairment in myotonic dystrophy type 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15557517" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Severe cardiac arrhythmias in young patients with myotonic dystrophy type 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8464127" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Relationship between parental trinucleotide GCT repeat length and severity of myotonic dystrophy in offspring.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1303233" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Correlation between CTG trinucleotide repeat length and frequency of severe congenital myotonic dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15185171" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Intergenerational instability of the expanded CTG repeat in the DMPK gene: studies in human gametes and preimplantation embryos.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8064819" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : A case of paternally inherited congenital myotonic dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7936256" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Congenital myotonic dystrophy transmitted from an asymptomatic father with a DM-specific gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9258965" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Haplotype analysis of congenital myotonic dystrophy patients from asymptomatic DM father.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9391889" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Paternal transmission of congenital myotonic dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10722967" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Congenital myotonic dystrophy: report of paternal transmission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8503448" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Size of the unstable CTG repeat sequence in relation to phenotype and parental transmission in myotonic dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11807903" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Paternal transmission of the congenital form of myotonic dystrophy type 1: a new case and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19459914" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Cognition and adaptive skills in myotonic dystrophy type 1: a study of 55 individuals with congenital and childhood forms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22861906" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Psychiatric and cognitive phenotype of childhood myotonic dystrophy type 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21592796" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : A new window on neurocognitive dysfunction in the childhood form of myotonic dystrophy type 1 (DM1).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17892958" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Myotonic dystrophy type I in childhood Long-term evolution in patients surviving the neonatal period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26566479" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Congenital and childhood myotonic dystrophy: Current aspects of disease and future directions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14760317" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Prevalence of structural cardiac abnormalities in patients with myotonic dystrophy type I.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8650827" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Myotonic dystrophy: relative sensitivity of symptoms signs and abnormal investigations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17043296" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Myotonic dystrophy: practical issues relating to assessment of strength.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25380585" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Natural history of skeletal muscle involvement in myotonic dystrophy type 1: a retrospective study in 204 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25380585" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Natural history of skeletal muscle involvement in myotonic dystrophy type 1: a retrospective study in 204 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12774952" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Quantitative motor assessment in myotonic dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16199443" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Falls and stumbles in myotonic dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15503094" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Myotonic dystrophy type 2 and related myotonic disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8058147" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Proximal myotonic myopathy: a new dominant disorder with myotonia, muscle weakness, and cataracts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9196902" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Proximal myotonic dystrophy--a family with autosomal dominant muscular dystrophy, cataracts, hearing loss and hypogonadism: heterogeneity of proximal myotonic syndromes?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25186227" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Phenotypic variability and molecular genetics in proximal myotonic myopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19208413" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Myotonic dystrophy type 2 with focal asymmetric muscle weakness and no electrical myotonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15770660" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Clinical and molecular aspects of the myotonic dystrophies: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22190310" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Pain in patients with myotonic dystrophy type 2: a postal survey in Finland.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15596616" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Musculoskeletal pain in patients with myotonic dystrophy type 2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33458578" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Myotonic dystrophy type 2: the 2020 update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29601898" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Qualitative and Quantitative Aspects of Pain in Patients With Myotonic Dystrophy Type 2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26581301" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Patient-Reported Impact of Symptoms in Myotonic Dystrophy Type 2 (PRISM-2).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18975316" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Myotonic dystrophy type 2 found in two of sixty-three persons diagnosed as having fibromyalgia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24742887" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Cardiac involvement in myotonic dystrophy: a nationwide cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7977052" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Cardiac involvement in myotonic dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2202157" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Electrocardiographic abnormalities in patients with myotonic dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1992371" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Myotonic heart disease: a clinical follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3365873" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : The natural history of cardiac involvement in myotonic dystrophy: an eight-year follow-up in 17 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15623712" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Sudden cardiac death in myotonic dystrophy type 2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18565861" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33150426" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Electrocardiographic predictors of infrahissian conduction disturbances in myotonic dystrophy type 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33812832" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : A Normal Electrocardiogram Does Not Exclude Infra-Hisian Conduction Disease in Patients With Myotonic Dystrophy Type 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33573883" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Prevalence of atrial fibrillation in myotonic dystrophy type 1: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26172955" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Relative risks for comorbidities associated with myotonic dystrophy: A population-based analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19481939" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Left ventricular dysfunction and cardiac arrhythmias are frequent in type 2 myotonic dystrophy: a case control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1614221" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Pulmonary function and resting breathing pattern in myotonic dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17239222" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Anaesthesiological and ventilatory precautions during cardiac surgery in Steinert's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16243623" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Sleep and neuromuscular disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28366348" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Quality of life and excessive daytime sleepiness in children and adolescents with myotonic dystrophy type 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23430686" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Daytime sleepiness and myotonic dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9484393" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Loss of serotonin-containing neurons in the raphe of patients with myotonic dystrophy: a quantitative immunohistochemical study and relation to hypersomnia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14996041" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Sleep complaints in patients with myotonic dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22786587" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20798200" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Poor sleep quality and fatigue but no excessive daytime sleepiness in myotonic dystrophy type 2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2116473" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Hypothalamic-pituitary-testicular function in 70 patients with myotonic dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22349862" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Endocrine function in 97 patients with myotonic dystrophy type 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24399868" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Hypogonadism and erectile dysfunction in myotonic dystrophy type 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8819213" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Gastrointestinal symptoms in myotonic dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16609987" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Gastrointestinal manifestations in myotonic muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18602828" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Gastrointestinal involvement is frequent in Myotonic Dystrophy type 2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19167224" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Dysphagia is present but mild in myotonic dystrophy type 2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16544320" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Cognitive impairment in neuromuscular disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10496264" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Reduced cerebral blood flow and impaired visual-spatial function in proximal myotonic myopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14678804" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Executive dysfunction and avoidant personality trait in myotonic dystrophy type 1 (DM-1) and in proximal myotonic myopathy (PROMM/DM-2).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16864839" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Subtle cognitive dysfunction in adult onset myotonic dystrophy type 1 (DM1) and type 2 (DM2).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17385090" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Cognitive impairment in adult myotonic dystrophies: a longitudinal study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29343467" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Hearing impairment in patients with myotonic dystrophy type 2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16908743" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Laboratory abnormalities in ambulatory patients with myotonic dystrophy type 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9649014" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Abnormal liver test results in myotonic dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1249576" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Dystrophia myotonica. Peripheral nerve involvement and pathogenetic implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1332841" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Peripheral neuropathy in myotonic dystrophy: electrophysiological and clinical features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/718472" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Peripheral neuropathy in myotonic dystrophy. Relation to glucose intolerance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22166607" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Cancer risk among patients with myotonic muscular dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19642006" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Hypothesis: neoplasms in myotonic dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19949042" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Neuroimaging in myotonic dystrophy type 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33237431" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Longitudinal study in patients with myotonic dystrophy type 1: correlation of brain MRI abnormalities with cognitive performances.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17486579" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Cerebral involvement in myotonic dystrophies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19224318" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Grey and white matter loss along cerebral midline structures in myotonic dystrophy type 2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10842259" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Triplet repeat expansion in neuromuscular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15099870" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Outcome in pregnancies complicated by myotonic dystrophy: a study of 31 patients and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16505316" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Outcome and effect of pregnancy in myotonic dystrophy type 2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15704146" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Hyper-CK-emia as the sole manifestation of myotonic dystrophy type 2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33624941" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : High throughput screening for expanded CTG repeats in myotonic dystrophy type 1 using melt curve analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17230537" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Severity, type, and distribution of myotonic discharges are different in type 1 and type 2 myotonic dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20513102" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Absent, unrecognized, and minimal myotonic discharges in myotonic dystrophy type 2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18067134" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Differential diagnosis of myotonic disorders.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
